25 results
Thumbnail

D2. 259 - A Comprehensive Decision Algorithm for Hypersensitivity Reactions to Iodinated Contrast Media in a Tertiary Care Setting

Thumbnail

D2.255 - NSAID Hypersensitivity Records: Assessing Documentation Practice, Challenges, and Areas for Improvement

Thumbnail

D2.256 - Cytokine release reaction after subcutaneous daratumumab

Thumbnail

D2.246 - Anaphylaxis to sugammadex in a 15 year-old-girl

Thumbnail

D2.247 - Sensitization to Meloxicam, Celecoxib and Paracetamol in patients intolerant to non-steroidal antiinflamatory drugs (NSAIDS)

Thumbnail

D2.248 - Allergy to quinolones: a clinical case

Thumbnail

D2.249 - Application of Desensitization Protocol with Rituximab in the Treatment of Corticosteroid-Dependent Nephrotic Syndrome in an Adolescent

Thumbnail

D2.250 - Can drug allergy develop in x-linked agammaglobulinemia (xla)? case report

Thumbnail

D2.251 - Anaphylaxis due to Andrographis panniculata - an emerging problem

Thumbnail

D2.252 - Confirmation of selectivity pattern to Non-Steroidal Anti-inflammatory Drugs: a retrospective study in a Central Hospital

Thumbnail

D2.253 - Is it possible to treat DRESS without systemic corticosteroids?

Thumbnail

D2.254 - Can a medication leave its mark on the skin?

Thumbnail

D2.257 - Anaphylaxis with FOLFOX scheme: not everything is Oxaliplatin

Thumbnail

D2.258 - Fixed drug eruption caused by co-amoxiclav

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes